Product Details
Tyenne
Tocilizumab400 mg/20 mL (20 mg/mL)
Concentrate for solution for infusion
Single-Use 20-mL Vial (Preservative-Free)
DIN/PIN/NPN
02552477
Manufacturer
Fresenius Kabi Canada Ltd.
Formulary Listing Date
2025-05-30
Unit Price
623.8050
Amount MOH Pays
623.8050
Coverage Status
Limited Use Product
ODB Formulary Therapeutic Classification
Therapeutic Note
NO
ATC Code
L04AC07
Interchangeable Products
NOLU Clinical Criteria
LU Code | Auth. Period | Clinical Criteria |
---|---|---|
697 | 1 year | For the treatment of rheumatoid arthritis (RA) in patients who have severe active disease (greater than or equal to 5 swollen joints and rheumatoid factor positive and/or, anti-CCP positive, and/or radiographic evidence of rheumatoid arthritis) and have experienced failure, intolerance, or have a contraindication to adequate trials of disease-modifying anti-rheumatic drugs (DMARDs) treatment regimens, such as one of the following combinations of treatments: A. i) Methotrexate (20mg/week) for at least 3 months, AND B. i) Methotrexate (20mg/week) for at least 3 months, AND C. i) Methotrexate (20mg/week), sulfasalazine (2g/day) and hydroxychloroquine (400mg/day) for at least 3 months. (Hydroxychloroquine is based by weight up to 400mg per day.); AND Tocilizumab is not being used in combination with another biologic drug used for the treatment of RA; AND Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology. Maintenance/Renewal: For second and subsequent renewals (i.e., beyond 2 years of ongoing use of tocilizumab) the patient must demonstrate objective evidence of preservation of treatment effect. For renewal of funding, tocilizumab must not be used in combination with another biologic for the treatment of RA and must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology. Recommended Dose: |
698 | 1 year | For the treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients who have active disease (greater than or equal to 3 swollen joints and greater than or equal to 5 active joints) despite a trial of optimal doses of subcutaneously administered methotrexate (i.e. 15 mg/m?2; per week) for at least 3 months. If the patient is unable to tolerate or has a contraindication to subcutaneous methotrexate, the nature of the intolerance or contraindication must be documented. Therapy must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology. Maintenance/Renewal: For second and subsequent renewals (i.e., beyond 2 years of ongoing use of tocilizumab) the patient must demonstrate objective evidence of preservation of treatment effect. For renewal of funding, tocilizumab must not be used in combination with another biologic for the treatment of pJIA and must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology. Recommended Dose:
The recommended subcutaneous (sc) dose of tocilizumab for patients 2 years of age and older:
|
720 | 1 year | For the treatment of systemic juvenile idiopathic arthritis (sJIA) in patients who meet all the following:
Maintenance/Renewals: For funding beyond the second year, the patient must demonstrate objective evidence of preservation of treatment effect. For renewal of funding, tocilizumab must not be used in combination with another biologic for the treatment of sJIA and must be prescribed by a rheumatologist or a prescriber with expertise in rheumatology. Recommended Dose: The recommended subcutaneous (sc) dose of tocilizumab for patients 2 years of age and older: |